Is Organon & Co (OGN) overvalued? · P/E 3.4, rev $6.40B
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
This page asks whether Organon & Co (OGN) looks expensive on cached numbers — not a short thesis.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next OGN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the OGN stock page for the full model, not this heading.
Not investment advice.